Simple blood test could catch myeloma years earlier in High-Risk groups
NCT ID NCT06644625
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This study aims to detect multiple myeloma at its earliest stage, called MGUS, using a simple blood test. It will screen 1,665 Black adults and close relatives of people with plasma cell disorders. The goal is to reduce delayed diagnosis and improve outcomes by catching the disease before it progresses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Blood draw for MGUS screening
- What this could lead to
- If successful, this screening approach could help catch multiple myeloma at an earlier, more treatable stage, potentially improving long-term survival.
- What could go wrong
- This is an early pilot study focused on feasibility, not yet proven to reduce harm. Many people with MGUS never develop myeloma, so screening may cause unnecessary worry or testing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atrium Health Levine Cancer
RECRUITINGCharlotte, North Carolina, 28204, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can a Two-Drug combo outsmart resistant myeloma?